References
- Abida, W., Patnaik, A., Campbell, D., Shapiro, J., Bryce, A. H., McDermott, R., Sautois, B., Vogelzang, N. J., Bambury, R. M., Voog, E. et al. (2020). Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration. J. Clin. Oncol., 38 (32), 3763–3772.10.1200/JCO.20.01035765502132795228
- Albers, P., Bögemann, M., Machtens, S., Merseburger, A. S., Schostak, M., Steuber, T., Wulfung, C., De Santis, M. (2020). Therapie des meta-stasierten Prostatakarzinoms im Wandel — neue Daten und offene Fragen. Der Urologe A., 59 (3), 307–317.10.1007/s00120-019-01072-031781782
- Amsberg von G., Merseburger, A. S. (2020). Therapie des metastasierten kastrationsresistenten Prostatakarzinoms. Urologe A., 59 (6), 673–680.10.1007/s00120-020-01187-932274540
- Angelergues, A., Efstathiou, E., Gyftaki, R., Wysocki, P. J., Lainez, N., Gonzalez, I., Castellano, D. E., Ozguroglu, M., Carbonero, I. G., Flechon, A. et al. (2018). Results of the FLAC European Database of Metastatic Castration-Resistant Prostate Cancer Patients Treated With Docetaxel, Cabazitaxel, and Androgen Receptor-Targeted Agents. Clin. Genitourin Cancer, 16 (4), e777–e784.10.1016/j.clgc.2018.02.01629550200
- Antonarakis, E. S., Piulats, J. M., Gross-Goupil, M., Goh, J., Ojamaa, K., Hoimes, C. J., Vaishampayan, U., Berger, R., Sezer, A., Alanko, T. et al. (2020). Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: Multicohort, open-label phase II KEYNOTE-199 study. J. Clin. Oncol., 38 (5), 395–405.10.1200/JCO.19.01638718658331774688
- Armstrong, A. J., Szmulewitz, R. Z., Petrylak, D. P., Holzbeierlein, J., Villers, A., Azad, A., Alcaraz, A., Alekseev, B., Iguchi, T., Shore, N. D. et al. (2019). ARCHES: A randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J. Clin. Oncol., 37 (32), 2974–2986.10.1200/JCO.19.00799683990531329516
- Attard, G., Borre, M., Gurney, H., Loriot, Y., Andresen-Daniil, C., Kalleda, R., Pham, T., Taplin, M. E. (2018). Abiraterone alone or in combination with enzalutamide in metastatic castration-resistant prostate cancer with rising prostate-specific antigen during enzalutamide treatment. J. Clin. Oncol., 36 (25), 2639–2646.10.1200/JCO.2018.77.9827611840530028657
- Beer, T. M., Armstrong, A. J., Rathkopf, D. E., Loriot, Y., Sternberg, C. N., Higano, C. S., Iversen, P., Bhattacharya, S., Carles, J., Chowdhury, S., et al. (2014). Enzalutamide in metastatic prostate cancer before chemotherapy. New Engl. J. Med., 371 (5), 424–433.10.1056/NEJMoa1405095441893124881730
- Boevé, L. M. S., Hulshof, M. C. C. M., Vis, A. N., Zwinderman, A. H., Twisk, J. W. R., Witjes, W. P. J. Delaere, K. P. J., van Moorselaar, R. J. A., Verhage, P. C. M. S., van Andel, G. (2019). Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary bone metastatic prostate cancer in a prospective randomised clinical trial: Data from the HORRAD trial. Eur. Urol., 75 (3), 410–418.10.1016/j.eururo.2018.09.00830266309
- Caffo, O., Bria, E., Giorgi, U. D., Tucci, M., Galli, L., Fratino, L., Rosseti, S., Iacovelli, R., Re, G. R., Mosillo, C. et al. (2017). Outcomes of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with different new agents (NAs) sequence in post-docetaxel (DOC) setting: Final analysis from a multicenter Italian study. J. Clin. Oncol., 35 (15), 5030.10.1200/JCO.2017.35.15_suppl.5030
- Chi, K. N., Agarwal, N., Bjartell, A., Chung, B. H., Pereira de Santana Gomes, A. J., Given, R., Juárez Soto, Á., Merseburger, A. S., Özgüroğlu, M., Uemura, H. et al. (2019). Apalutamide for metastatic, castration-sensitive prostate cancer. New Engl. J. Med., 381 (1), 13–24.10.1056/NEJMoa1903307
- Chi, K. N., Protheroe, A., Rodríguez-Antolín, A., Facchini, G., Suttman, H., Matsubara, N., Ye, Z., Keam, B., Damião, R., Li, T., McQuarrie, K. et al. (2018). Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): An international, randomised phase 3 trial. Lancet Oncol., 19 (2), 194–206.10.1016/S1470-2045(17)30911-7
- Clarke, N., Wiechno, P., Alekseev, B., Sala, N., Jones, R., Kocak, I., Chiuri, V. E., Jassem, J., Fléchon, A., Redfern, C. et al. (2018). Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: A randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol., 19 (7), 975–986.10.1016/S1470-2045(18)30365-6
- Cornford, P., Bellmunt, J., Bolla, M., Briers, E., De Santis, M., Gross, T., Henry, A. M., Joniau, S., Lam, T. B., Mason, M. D. et al. (2017). EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of relaps g, metastatic, and castration-resistant prostate cancer. Eur. Urol., 71 (4), 630–642.10.1016/j.eururo.2016.08.002
- Davis, I. D., Martin, A. J., Stockler, M. R., Begbie, S., Chi, K. N., Chowdhury, S., Coskinas, X., Frydenberg, M., Hague, W. E., Horvath, L. G. et al. (2019). Enzalutamide with standard first-line therapy in metastatic prostate cancer. New Engl. J. Med., 381 (2), 121–131.10.1056/NEJMoa190383531157964
- De Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B. J., Saad, F. et al. (2011). COU-AA-301 Investigators. Abiraterone and increased survival in meta-static prostate cancer. New Engl. J. Med., 364 (21), 1995–2005.10.1056/NEJMoa1014618
- De Bono, J. S., Mateo, J., Fizazi, K., Saad, F., Shore, N., Sandhu, S., Chi, K. N., Sartor, O., Agarwal, N., Olmos, D. et al. (2020a). Olaparib for meta-static castration-resistant prostate cancer. New Engl. J. Med., 382 (22), 2091–2102.10.1056/NEJMoa191144032343890
- De Bono, J. S., Mehra, N., Higano, C. S., Saad, F., Buttigliero, C., Mata, M., Chen, H. C., Healy, C. G., Paccagnella, M. L., Czibere, A. et al. (2020b). TALAPRO- 1: A phase II study of talazoparib (TALA) in men with DNA damage repair mutations (DDRmut) and metastatic castration-resistant prostate cancer (mCRPC) — First interim analysis (IA). J. Clin. Oncol., 38 (6), 119.10.1200/JCO.2020.38.6_suppl.119
- De Bono, J. S., Oudard, S., Ozguroglu, M., Hansen, S., Machiels, J. P., Kocak, I., Gravis, G., Bodrogi, I., Mackenzie, M. J., Shen, L. et al. (2010). Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. Lancet, 376 (9747), 1147–1154.10.1016/S0140-6736(10)61389-X
- Dienstmann, R., Dong, F., Borger, D., Dias-Santagata, D., Ellisen, L. W., Le, L. P., Iafrate, A. J. (2014). Standardized decision support in next generation sequencing reports of somatic cancer variants. Mol. Oncol., 8 (5), 859–873.10.1016/j.molonc.2014.03.021552852724768039
- Eisenberger, M., Hardy-Bessard, A. C., Kim, C. S., Géczi, L., Ford, D., Mourey, L., Carles, J., Parente, P., Font, A., Kacso, G. et al. (2017). Phase III study comparing a reduced dose of cabazitaxel (20 mg/m2) and the currently approved dose (25 mg/m2) in postdocetaxel patients with metastatic castration-resistant prostate cancer-PROSELICA. J. Clin. Oncol., 35 (28), 3198–3206.10.1200/JCO.2016.72.107628809610
- Fendler, W. P., Weber, M., Iravani, A., Hofman, M. S., Calais, J., Czernin, J., Ilhan, H., Saad, F., Small, E. J., Smith, M. R. et al. (2019). Prostate-specific membrane antigen ligand positron emission tomography in men with nonmetastatic castration-resistant prostate cancer. Clin. Cancer Res., 25 (24), 7448–7454.10.1158/1078-0432.CCR-19-105031511295
- Fizazi, K., Shore, N. D., Tammela, T., Ulys, A., Vjaters, E., Polyakov, S., Jievaltas, M., Luz, M., Alekseev, B., Kuss, I. et al. (2020). Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for nonmetastatic castration-resistant prostate cancer (nmCRPC). J. Clin. Oncol., 38 (15), 5514.10.1200/JCO.2020.38.15_suppl.5514
- Folkmanis, K., Eglītis, J., Jakubovskis, M., Lietuvietis, V., Folkmane, I, Isajevs, S. (2021a). CD63 and DNA mismatch repair protein expression in prostate cancer. Proc. Latvian Acad. Sci., Section B, 75 (3), 180–185.10.2478/prolas-2021-0027
- Folkmanis, K., Junk, E., Merdane, E., Folkmanis, V., Folkmane, I., Isajevs, S. (2021b). New kids on the block” — the game changers. The role of immune check point blockade in personalised treatment of prostate, urinary bladder, and kidney cancer. Proc. Latvian Acad. Sci., Section B, 75 (3), 149–157.10.2478/prolas-2021-0024
- Gravis, G., Boher, J. M., Joly, F., Soulié, M., Albiges, L., Priou, F., Latorzeff, I., Delva, R., Krakowski, I., Laguerre, B. et al. (2016). Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: Impact of metastatic burden and long-term survival analysis of the randomized Phase 3 GETUG-AFU15 Trial. Eur. Urol., 70 (2), 256–262.10.1016/j.eururo.2015.11.005
- Gravis, G., Fizazi, K., Joly, F., Oudard, S., Priou, F., Esterni, B., Latorzeff, I., Delva, R., Krakowski, I., Laguerre, B. et al. (2013). Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): A randomised, open-label, phase 3 trial. Lancet Oncol., 14 (2), 149–158.10.1016/S1470-2045(12)70560-0
- Gundem, G., Van Loo, P., Kremeyer, B., Alexandrov, L. B., Tubio, J. M. C., Papaemmanuil, E. Brewer, D. S., Kallio, H. M. L., Högnäs, G., Annala, M. et al. (2015). Nature, 520, 353–357.10.1038/nature14347441303225830880
- Hussain, M., Fizazi, K., Saad, F., Rathenborg, P., Shore, N., Ferreira, U., Ivashchenko, P., Demirhan, E., Modelska, K., Phung, D., Krivoshik, A., Sternberg, C. N. (2018). Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. New Engl. J. Med., 378 (26), 2465–2474.10.1056/NEJMoa1800536828803429949494
- Hussain, M., Mateo, J., Fizazi, K., Saad, F., Shore, N. D., Sandhu, S., Chi, K. N., Sartor, O., Agarwal, N., Olmos, D., et al. (2019). LBA12_PRPROfound: Phase III study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations. Ann. Oncol., 30 (5), 881–882.10.1093/annonc/mdz394.039
- Khalaf, D., Annala, M., Finch D. L., Oja, C. C., Vergidis, J., Zulfiqar, M., Sunderland, K., Beja, K., Vanderkhove, G. R., Gleave, M., et al. (2018). Phase 2 randomized cross-over trial of abiraterone + prednisone vs enzalutamide for patients with mCPRC: Results for 2nd-line therapy. J. Clin. Oncol., 36 (15), 5015a.10.1200/JCO.2018.36.15_suppl.5015
- Knipper, S., Beyer, B., Mandel, P., Tennstedt, P., Tilki, D., Steuber, T., Freafen, M. (2020). Outcome of patients with newly diagnosed prostate cancer with low metastatic burden treated with radical prostatectomy: A comparison to STAMPEDE arm H. World J. Urol., 38 (6), 1459–1464.10.1007/s00345-019-02950-031511970
- Knipper, S., Mandel, P., Graefen, M. (2019). Lokale Therapie beim fort-geschrittenen und metastasierten Prostatakarzinom. Uro-News, 23, 36–39.10.1007/s00092-019-2185-2
- Koo, K. C., Lee, J. S., Ha, J. S., Han, K. S., Lee, K. S., Hah, Y. S., Rha, K. H., Hong, S. J., Chung, B. H. (2019). Optimal sequencing strategy using docetaxel and androgen receptor axis-targeted agents in patients with castration-resistant prostate cancer: Utilization of neutrophil-to-lymphocyte ratio. World J. Urol., 37 (11), 2375–2384.10.1007/s00345-019-02658-130734074
- Kretschmer, A., Todenhöfer, T. (2020). Systemische Therapie des fortgeschrittenen Prostatakarzinoms Urologe A., 59 (12), 1565–1576.10.1007/s00120-020-01381-9
- Kumar, J., Jazayeri, S. B., Gautam, S., Norez, D., Alam, M. U., Tanneru, K., Bazargani, S., Costa, J., Bandyk, M., Ganapathi, H. P., et al. (2020). Comparative efficacy of apalutamide darolutamide and enzalutamide for treatment of non-metastatic castrate-resistant prostate cancer: a systematic review and network meta-analysis. Urol. Oncol., 38 (11), 826–834.10.1016/j.urolonc.2020.03.022
- Kyriakopoulos, C. E., Chen, Y. H., Carducci, M. A., Liu, G., Jarrard, D. F., Hahn, N. M., Shevrin, D. H., Dreicer, R., Hussain, M., Eisenberger, M., et al. (2018). Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: Long-term survival analysis of the randomized phase III E3805 CHAARTED trial. J. Clin. Oncol., 36 (11), 1080–1087.10.1200/JCO.2017.75.3657
- Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015). PD-1 blockade in tumors with mismatch-repair deficiency. New Engl. J. Med., 372 (26), 2509–2520.10.1056/NEJMoa1500596
- Li, M. M., Datto, M., Duncavage, E. J., Kulkarni, S., Lindeman, N. I., Roy, S., Tsimberidou, A. M., Vnencak-Jones, C. L., Wolff, D. J., Younes, A., et al. (2017). Standards and guidelines for the interpretation and reporting of sequence variants in cancer: A joint consensus recommendation of the association for molecular pathology, American Society of Clinical Oncology, and College of American Pathologists. J. Mol. Diagn., 19 (1), 4–23.10.1016/j.jmoldx.2016.10.002
- Lotan, T, L., Tomlins, S. A., Bismar, T. A., Van der Kwast, T. H., Grignon, D., Egevad, L., Kristiansen, G., Pritchard, C. C., Rubin, M. A., Bubendorf, L. (2020). Report from the International Society of Urological Pathology (ISUP) Consultation Conference on Molecular Pathology of Urogenital Cancers. I. Molecular biomarkers in prostate cancer. Ann. J. Surg. Pathol., 44 (7), e15–e29.10.1097/PAS.0000000000001450
- Mottet, N., Cornford, P., van den Bergh, R. C. N., De Santis, M., Fanti, S., Gillessen, S., Grummet, J., Henry, A. M., Lam, T. B., Mason, M. D., et al. (2020). EAU – ESTRO – ESUR – SIOG Guidelines on Prostate Cancer. EAU Guidelines Office, Arnhem.
- Parker, C. C., James, N. D., Brawley, C. D., Clarke, N. W., Hoyle, A. P., Ali, A., Ritchie, A. W. S., Attard, G., Chowdhury, S., Cross, W., et al. (2018). Systemic Therapy for Advanced or Metastatic Prostate cancer: Evaluation of Drug Efficacy (STAMPEDE) investigators. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): A randomised controlled phase 3 trial. Lancet, 392 (10162), 2353–2366.
- Parker, C., Nilsson, S., Heinrich, D., Helle, S. I., O’Sullivan, J. M., Fosså, S. D., Chodacki, A., Wiechno, P., Logue, J., Seke, M., et al. (2013). Alpha emitter radium-223 and survival in metastatic prostate cancer. New Engl. J. Med., 369 (3), 213–223.10.1056/NEJMoa1213755
- Roach, M. 3rd, Hanks, G., Thames H. J., Schellhammer, P., Shipley, W. U., Sokol G. H., Sandler, H., et al. (2006). Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int. J. Radiat. Oncol. Biol. Phys. 65, 965–974.10.1016/j.ijrobp.2006.04.029
- Ryan, C. J., Smith, M. R., Fizazi, K., Saad, F., Mulders, P. F., Sternberg, C. N., Miller, K., Logothetis, C. J., Shore, N. D., Small, E. J., et al. (2015). Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): Final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol., 16 (2), 152–160.10.1016/S1470-2045(14)71205-7
- Scher, H. I., Fizazi, K., Saad, F., Taplin, M. E., Sternberg, C. N., Miller, K., de Wit, R., Mulders, P., Chi, K. N., Shore, N. D., Armstrong, A. J., et al. (2012). Increased survival with enzalutamide in prostate cancer after chemotherapy. New Engl. J. Med., 367 (13), 1187–1197.10.1056/NEJMoa120750622894553
- Smith, M. R., Fizazi, K., Sandhu, S. K., Kelly, W. K., Efstathiou, E., Lara, P., Yu, E.Y., George, D. J., Chi, K. N., Saad, F., et al. (2020). Niraparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD): Correlative measures of tumor response in phase II GALAHAD study. J. Clin. Oncol., 38 (6), 118.10.1200/JCO.2020.38.6_suppl.118
- Smith, M. R., Saad, F., Chowdhury, S., Oudard, S., Hadaschik, B. A., Graff, J. N., Olmos, D., Mainwaring, P. N., Lee, J. Y., Uemura, H. et al. (2018). Apalutamide treatment and metastasis-free survival in prostate cancer. New. Engl. J. Med., 378 (15), 1408–1418.10.1056/NEJMoa171554629420164
- Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004). Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. New Engl. J. Med. 351 (15), 1502–1512.10.1056/NEJMoa04072015470213
- Thomas, C., Ohlmann, C. H. (2020) Combination therapy for metastatic hormone- sensitive prostate cancer: What? When? For whom? Urologe A., 59 (6), 665–672.10.1007/s00120-020-01189-7
- Tu, X., Chang, T., Nie, L., Qiu, S., Xu, H., Huang, Y., Bao, Y., Liu, Z., Yang, L., Wei, Q. (2019). Neuroendocrine carcinoma of the prostate: A sytematic review and pooled analysis. Urol. Int., 203, 383–390.10.1159/00049988330965328